Codiak BioSciences Inc.

11.75-1.13-8.77%Vol 167.12K1Y Perf -3.22%
Apr 19th, 2021 16:00 DELAYED
BID11.75 ASK11.82
Open12.70 Previous Close12.88
Pre-Market- After-Market-
 - -  - -%
Target Price
34.00 
Analyst Rating
— — 0.00
Potential %
189.36 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★ —    46.20
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap258.43M 
Earnings Rating
Price Range Ratio 52W %
12.85 
Earnings Date
18th Mar 2021

Today's Price Range

11.6413.20

52W Range

7.9037.85

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-13.98%
1 Month
-28.66%
3 Months
-57.04%
6 Months
1.21%
1 Year
-3.22%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CDAK11.75-1.1300-8.77
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.11-1.14-2.70
Q03 2020-3.94-12.83-225.63
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-1.11
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume167.12K
Shares Outstanding21.99M
Trades Count2.26K
Dollar Volume1.64M
Avg. Volume148.60K
Avg. Weekly Volume143.03K
Avg. Monthly Volume139.64K
Avg. Quarterly Volume142.22K

Codiak BioSciences Inc. (NASDAQ: CDAK) stock closed at 11.75 per share at the end of the most recent trading day (a -8.77% change compared to the prior day closing price) with a volume of 167.12K shares and market capitalization of 258.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 101 people. Codiak BioSciences Inc. CEO is Douglas E. Williams.

The one-year performance of Codiak BioSciences Inc. stock is -3.22%, while year-to-date (YTD) performance is -63.62%. CDAK stock has a five-year performance of %. Its 52-week range is between 7.9 and 37.85, which gives CDAK stock a 52-week price range ratio of 12.85%

Codiak BioSciences Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 19.45, a price-to-sale (PS) ratio of 97.18, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -73.85%, a ROC of -% and a ROE of 104.92%. The company’s profit margin is -%, its EBITDA margin is -6 235.50%, and its revenue ttm is $2.92 Million , which makes it $0.13 revenue per share.

Of the last four earnings reports from Codiak BioSciences Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.11 for the next earnings report. Codiak BioSciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Codiak BioSciences Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Codiak BioSciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Codiak BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Codiak BioSciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.22, ATR14 : 2.09, CCI20 : -170.89, Chaikin Money Flow : -0.24, MACD : -2.61, Money Flow Index : 43.71, ROC : -22.08, RSI : 27.61, STOCH (14,3) : 2.53, STOCH RSI : 0.00, UO : 37.79, Williams %R : -97.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Codiak BioSciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Codiak BioSciences Inc.

Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.

CEO: Douglas E. Williams

Telephone: +1 617 949-4100

Address: 35 CambridgePark Drive, Cambridge 02140, MA, US

Number of employees: 101

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits